Measured product lead custody receipt.
github.com/Zer0pa/Synthetic-BiologyRESEARCH-READY
LIVE
WET-LAB OPEN
Pre-Laboratory Cell Pathway Design
Synthetic-Biology · zer0pa-synbio 0.1.0 · github.com/Zer0pa/Synthetic-Biology
An in-silico pipeline for engineering human-milk oligosaccharide biosynthesis in E. coli. Three HMO targets — 2'-FL, 3'-SL, and DSLNT — flow through a seven-stage design stack and exit as SBOL3-attested packets a wet lab can pick up.
Every packet carries an explicit scientific_valid: False flag. The design dossier is real and inspectable; the biology has not been confirmed at the bench, and the page does not claim it has.
01 · THE GAPSTRUCTURE VS SCIENCE
“Synthetic-biology design work needs structural status. scientific validation stays separate.”
02 · MARKETSUSER FIT
Best fit: design teams sending HMO pathway packets to a wet lab before fermentation, scale-up, or regulatory work begins.
03 · VALUE
DESIGNQA
Hash-bound design packets with SBOL3 attestation and a scientific-validity flag that travels with every HMO target.
04 · INSIGHT
Design packets pass shape checks; the biology is not yet proven.
05.0 · CURRENT TECHDESIGN ARTIFACT MIX
Synthetic-biology design today scatters across SBOL files, pathway hypotheses, COBRApy model dumps, structure-prediction outputs, and wet-lab planning notes. The bench team receives a folder of attachments and reconstructs intent from filenames, version drift, and email threads.
05.1 · OUR TECHSTRUCTURAL CHECK + COMMITTED FALSE
This pipeline ships a single packet per HMO target. 3/3 structural PASS covers 2'-FL, 3'-SL, and DSLNT through schema, boundary, license-class, and SBOL3 attestation checks; the same packet commits scientific_valid: False. A wet lab receives one object that names its targets, its constraints, and the line between what was designed and what was tested.
05.2 · BENCHMARKSSTRUCTURAL · COMMITTED PACKETS
HMO targets3/3structural PASS
CPU tests2560 regressions
Checks23Tier A/B/C list
PyPI0.1.0stale pending
Current status: structural conformance only · PyPI 0.1.0 stale-pending ·
scientific_valid: False on every committed HMO packet.06 · MEASUREMENTSTRUCTURAL VERIFY · 23 CHECKS
23 checks confirm three HMO design packets are well-formed, not bench-tested.
06.1 · COMPARATIVE / BOUNDED VALIDATION · STRUCTURAL VS SCIENTIFIC STATUS
The 2'-FL, 3'-SL, and DSLNT packets clear schema, boundary, license-class, and SBOL3 attestation under 23 tiered checks. Structural conformance is real; wet-lab HMO synthesis is not presented in this release.
07 · KEY METRICSSYNBIO V0.1 · STRUCTURAL-ONLY ANCHORS
07.1 · STRUCTURAL CHECK
3/3
2'-FL, 3'-SL, DSLNT · structural pass on all three HMO targets
07.2 · CPU TESTS
256PASS
pytest tests/ · 0 regressions, 59 GPU calls skipped07.3 · CHECK LIST
23
Tier A, B, and C checks loaded at packet build
07.4 · PYPI RELEASE
0.1.0STALE
zer0pa-synbio · connected, stale pending fresh release07.5 · SCIENTIFIC HMO
false
Packet flag ·
scientific_valid: False committed on every HMO target08 · DETERMINISMSTRUCTURAL SHA · NOT BIOLOGY
Structural hashes repeat; scientific validity is not determined.
08.1 · WHAT DETERMINISTIC MEANSSTRUCTURAL SHA + VALIDITY FLAGS
Each HMO design is hashed across three target shapes — 2'-FL, 3'-SL, and DSLNT — over envelope schema, boundary SHA, SBOL3 attestation, license-class enforcement, and the tiered check list. Re-running the pipeline produces the same SHA. That is what the 3/3 PASS measures.
Structural replay does not promote any biological claim. The scientific_valid: False flag stays committed on every packet until a wet-lab result is independently produced and attached under a separate validation contract. Determinism is per-envelope-shape, structural only.
08.2 · THE FIDELITY GAP
Honest Blocker ·
The public 0.1.0 PyPI surface remains stale-pending while HMO packets at validation/hmo-seed-evidence/{2pFL,3pSL,DSLNT}/RESULT.md report scientific_valid: False in stub mode. The structural check is real; wet-lab HMO synthesis, RFdiffusion closure, and a fresh release are still ahead.
09
FIVE PATHS FROM ONE design packet.
09.1 · THIS REPO'S AMBITION
The ambition is a credible front end for synthetic-biology design — one packet per pathway, carrying its sequence context, boundary constraints, license class, naming history, and validity status. A bioengineer should be able to pick it up on a Tuesday morning and walk into the lab knowing exactly what is designed and what is not yet proven.
09.2 · WHAT WORKS NOW
Three HMO design packets ship with structural conformance, SBOL3 attestation, and explicit validity flags on every target.
09.3 · WHAT'S STILL OPEN
Wet-lab HMO synthesis, GPU-bound structural calls, and a fresh PyPI release remain ahead of this version.
09.4 · DESIGN REVIEW · NEAR-TERM (12–24 MO)
Wet labs stop redoing design review
A bioengineering team that receives a packet with sequence context, license class, and validity flags already attached can spend its Monday morning planning cloning, not re-checking whether the upstream design was even meant to be tested yet.
09.5 · INFANT NUTRITION · NEAR-TERM (12–24 MO)
HMO programs gain a planning standard
Infant-nutrition and prebiotic teams chasing 2'-FL, 3'-SL, and DSLNT can compare external design proposals against an open structural template. Vendor pitches become easier to read because the pipeline names what was checked and what was not.
09.6 · BIOFOUNDRY INTAKE · MID-TERM (24–48 MO)
Biofoundries take work from packets
A biofoundry can accept design jobs as structured packets instead of slide decks and PDFs. Intake becomes a checklist against the packet's declared status, which shortens the conversation between the design house and the strain-build team.
09.7 · PROCUREMENT · MID-TERM (24–48 MO)
Buyers separate design riskfrom biology risk
A pharma or food-ingredient buyer evaluating a synthetic-biology proposal can ask for design-side dossiers before any wet-lab commit. Procurement gains a way to price design maturity and bench risk as two different line items.
09.8 · INDUSTRY STANDARD · PARADIGM (48 MO+)
Synthetic biology adopts handoff packets
If structured design packets become how synthetic-biology programs travel between teams, the field inherits a shared object that survives staff turnover, vendor changes, and regulatory review. The pathway design becomes a durable asset, not a slide.